NCT03034460

Efficacy and Safety of CD5024 1% in Acne Vulgaris

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 70 (actual)
• Sponsor: Galderma R&D · Industry
• Sex: All
• Age: 18 Years – 35 Years
• Healthy volunteers: Not accepted

Summary

Exploratory, multi-center, randomised, investigator-blinded, vehicle controlled study using intra-individual comparison involving subjects with acne vulgaris on face to evaluate the efficacy of CD5024 1% cream over a 6-week treatment period compared to its vehicle.

Detailed description

Study drugs application will be performed once daily, 5 days a week during 6 weeks

Conditions

• Acne

Interventions

Type	Name	Description
DRUG	CD5024 1% cream	500 µL on half-face, five days a week during 6 weeks
DRUG	CD5024 cream placebo	500 µL on half-face, five days a week during 6 weeks
DRUG	CD0271/CD1579 gel	500 µL on half-face, five days a week during 6 weeks
DRUG	CD0271/CD1579 gel placebo	500 µL on half-face, five days a week during 6 weeks

Timeline

• Start date: 2016-04-25
• Primary completion: 2016-11-02
• Completion: 2016-11-02
• First posted: 2017-01-27
• Last updated: 2020-12-11
• Results posted: 2020-12-11

Locations

7 sites across 3 countries: Canada, France, Germany